Last reviewed · How we verify
Sociedad Andaluza de Enfermedades Infecciosas — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Triple therapy with ritonavir | Triple therapy with ritonavir | marketed | HIV protease inhibitor | HIV-1 protease | Infectious Disease |
Therapeutic area mix
- Infectious Disease · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Baqiyatallah Medical Sciences University · 1 shared drug class
- Bristol-Myers Squibb · 1 shared drug class
- Community Research Initiative of New England · 1 shared drug class
- Drugs for Neglected Diseases · 1 shared drug class
- DualityBio Inc. · 1 shared drug class
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 shared drug class
- Far East Bio-Tec Co., Ltd · 1 shared drug class
- Abbott · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Sociedad Andaluza de Enfermedades Infecciosas:
- Sociedad Andaluza de Enfermedades Infecciosas pipeline updates — RSS
- Sociedad Andaluza de Enfermedades Infecciosas pipeline updates — Atom
- Sociedad Andaluza de Enfermedades Infecciosas pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Sociedad Andaluza de Enfermedades Infecciosas — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sociedad-andaluza-de-enfermedades-infecciosas. Accessed 2026-05-17.